Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
The global Antivenom market is projected to reach US$ 1283.7 million by 2030 from an estimated US$ 1002.9 million in 2024, at a CAGR of 4.2% during 2024 and 2030.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antivenom, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Antivenom.
The Antivenom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antivenom market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antivenom manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
麻豆原创 Segmentation
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent antivenom
Monovalent antivenom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Antivenom in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antivenom sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Antivenom Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Antivenom 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Polyvalent antivenom
1.2.3 Monovalent antivenom
1.3 麻豆原创 by Application
1.3.1 Global Antivenom 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Antivenom 麻豆原创 Size Estimates and Forecasts
2.1.1 Global Antivenom Revenue 2019-2030
2.1.2 Global Antivenom Sales 2019-2030
2.2 Antivenom 麻豆原创 Size by Region: 2023 Versus 2030
2.3 Antivenom Sales by Region (2019-2030)
2.3.1 Global Antivenom Sales by Region: 2019-2024
2.3.2 Global Antivenom Sales Forecast by Region (2025-2030)
2.3.3 Global Antivenom Sales 麻豆原创 Share by Region (2019-2030)
2.4 Antivenom 麻豆原创 Estimates and Projections by Region (2025-2030)
2.4.1 Global Antivenom Revenue by Region: 2019-2024
2.4.2 Global Antivenom Revenue Forecast by Region (2025-2030)
2.4.3 Global Antivenom Revenue 麻豆原创 Share by Region (2019-2030)
3 Global Antivenom by Manufacturers
3.1 Global Top Antivenom Manufacturers by Sales
3.1.1 Global Antivenom Sales by Manufacturer (2019-2024)
3.1.2 Global Antivenom Sales 麻豆原创 Share by Manufacturer (2019-2024)
3.2 Global Top Antivenom Manufacturers by Revenue
3.2.1 Global Antivenom Revenue by Manufacturer (2019-2024)
3.2.2 Global Antivenom Revenue Share by Manufacturer (2019-2024)
3.3 Global Antivenom Price by Manufacturer (2019-2024)
3.4 Competitive Landscape
3.4.1 Key Antivenom Manufacturers Covered: Ranking by Revenue
3.4.2 Global Antivenom 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.4.3 Global Antivenom 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Antivenom Manufacturing Base Distribution, Product Type
3.5.1 Antivenom Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Antivenom Product Type
3.5.3 Date of International Manufacturers Enter into Antivenom 麻豆原创
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 CSL
4.1.1 CSL Company Information
4.1.2 CSL Description, Business Overview
4.1.3 CSL Antivenom Products Offered
4.1.4 CSL Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.1.5 CSL Antivenom Sales by Product in 2023
4.1.6 CSL Antivenom Sales by Application in 2023
4.1.7 CSL Antivenom Sales by Geographic Area in 2023
4.1.8 CSL Recent Developments
4.2 Merck
4.2.1 Merck Company Information
4.2.2 Merck Description, Business Overview
4.2.3 Merck Antivenom Products Offered
4.2.4 Merck Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.2.5 Merck Antivenom Sales by Product in 2023
4.2.6 Merck Antivenom Sales by Application in 2023
4.2.7 Merck Antivenom Sales by Geographic Area in 2023
4.2.8 Merck Recent Developments
4.3 BTG
4.3.1 BTG Company Information
4.3.2 BTG Description, Business Overview
4.3.3 BTG Antivenom Products Offered
4.3.4 BTG Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.3.5 BTG Antivenom Sales by Product in 2023
4.3.6 BTG Antivenom Sales by Application in 2023
4.3.7 BTG Antivenom Sales by Geographic Area in 2023
4.3.8 BTG Recent Developments
4.4 Pfizer
4.4.1 Pfizer Company Information
4.4.2 Pfizer Description, Business Overview
4.4.3 Pfizer Antivenom Products Offered
4.4.4 Pfizer Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.4.5 Pfizer Antivenom Sales by Product in 2023
4.4.6 Pfizer Antivenom Sales by Application in 2023
4.4.7 Pfizer Antivenom Sales by Geographic Area in 2023
4.4.8 Pfizer Recent Developments
4.5 Haffkine Bio-Pharmaceutical
4.5.1 Haffkine Bio-Pharmaceutical Company Information
4.5.2 Haffkine Bio-Pharmaceutical Description, Business Overview
4.5.3 Haffkine Bio-Pharmaceutical Antivenom Products Offered
4.5.4 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.5.5 Haffkine Bio-Pharmaceutical Antivenom Sales by Product in 2023
4.5.6 Haffkine Bio-Pharmaceutical Antivenom Sales by Application in 2023
4.5.7 Haffkine Bio-Pharmaceutical Antivenom Sales by Geographic Area in 2023
4.5.8 Haffkine Bio-Pharmaceutical Recent Developments
4.6 Rare Disease Therapeutics
4.6.1 Rare Disease Therapeutics Company Information
4.6.2 Rare Disease Therapeutics Description, Business Overview
4.6.3 Rare Disease Therapeutics Antivenom Products Offered
4.6.4 Rare Disease Therapeutics Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.6.5 Rare Disease Therapeutics Antivenom Sales by Product in 2023
4.6.6 Rare Disease Therapeutics Antivenom Sales by Application in 2023
4.6.7 Rare Disease Therapeutics Antivenom Sales by Geographic Area in 2023
4.6.8 Rare Disease Therapeutics Recent Development
4.7 Flynn Pharma
4.7.1 Flynn Pharma Company Information
4.7.2 Flynn Pharma Description, Business Overview
4.7.3 Flynn Pharma Antivenom Products Offered
4.7.4 Flynn Pharma Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.7.5 Flynn Pharma Antivenom Sales by Product in 2023
4.7.6 Flynn Pharma Antivenom Sales by Application in 2023
4.7.7 Flynn Pharma Antivenom Sales by Geographic Area in 2023
4.7.8 Flynn Pharma Recent Development
4.8 Vins Bioproducts
4.8.1 Vins Bioproducts Company Information
4.8.2 Vins Bioproducts Description, Business Overview
4.8.3 Vins Bioproducts Antivenom Products Offered
4.8.4 Vins Bioproducts Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.8.5 Vins Bioproducts Antivenom Sales by Product in 2023
4.8.6 Vins Bioproducts Antivenom Sales by Application in 2023
4.8.7 Vins Bioproducts Antivenom Sales by Geographic Area in 2023
4.8.8 Vins Bioproducts Recent Development
4.9 Bharat Serums and Vaccines
4.9.1 Bharat Serums and Vaccines Company Information
4.9.2 Bharat Serums and Vaccines Description, Business Overview
4.9.3 Bharat Serums and Vaccines Antivenom Products Offered
4.9.4 Bharat Serums and Vaccines Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.9.5 Bharat Serums and Vaccines Antivenom Sales by Product in 2023
4.9.6 Bharat Serums and Vaccines Antivenom Sales by Application in 2023
4.9.7 Bharat Serums and Vaccines Antivenom Sales by Geographic Area in 2023
4.9.8 Bharat Serums and Vaccines Recent Development
4.10 Serum Biotech
4.10.1 Serum Biotech Company Information
4.10.2 Serum Biotech Description, Business Overview
4.10.3 Serum Biotech Antivenom Products Offered
4.10.4 Serum Biotech Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.10.5 Serum Biotech Antivenom Sales by Product in 2023
4.10.6 Serum Biotech Antivenom Sales by Application in 2023
4.10.7 Serum Biotech Antivenom Sales by Geographic Area in 2023
4.10.8 Serum Biotech Recent Development
4.11 MicroPharm
4.11.1 MicroPharm Company Information
4.11.2 MicroPharm Description, Business Overview
4.11.3 MicroPharm Antivenom Products Offered
4.11.4 MicroPharm Antivenom Sales, Revenue and Gross Margin (2019-2024)
4.11.5 MicroPharm Antivenom Sales by Product in 2023
4.11.6 MicroPharm Antivenom Sales by Application in 2023
4.11.7 MicroPharm Antivenom Sales by Geographic Area in 2023
4.11.8 MicroPharm Recent Development
5 Breakdown Data by Type
5.1 Global Antivenom Sales by Type (2019-2030)
5.1.1 Global Antivenom Sales by Type (2019-2024)
5.1.2 Global Antivenom Sales Forecast by Type (2025-2030)
5.1.3 Global Antivenom Sales 麻豆原创 Share by Type (2019-2030)
5.2 Global Antivenom Revenue Forecast by Type (2019-2030)
5.2.1 Global Antivenom Revenue by Type (2019-2024)
5.2.2 Global Antivenom Revenue Forecast by Type (2025-2030)
5.2.3 Global Antivenom Revenue 麻豆原创 Share by Type (2019-2030)
5.3 Antivenom Average Selling Price (ASP) by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Antivenom Sales by Application (2019-2030)
6.1.1 Global Antivenom Sales by Application (2019-2024)
6.1.2 Global Antivenom Sales Forecast by Application (2025-2030)
6.1.3 Global Antivenom Sales 麻豆原创 Share by Application (2019-2030)
6.2 Global Antivenom Revenue Forecast by Application (2019-2030)
6.2.1 Global Antivenom Revenue by Application (2019-2024)
6.2.2 Global Antivenom Revenue Forecast by Application (2025-2030)
6.2.3 Global Antivenom Revenue 麻豆原创 Share by Application (2019-2030)
6.3 Antivenom Average Selling Price (ASP) by Application (2019-2030)
7 North America
7.1 North America Antivenom 麻豆原创 Size YoY Growth 2019-2030
7.2 North America Antivenom 麻豆原创 Facts & Figures by Country
7.2.1 North America Antivenom Sales by Country (2019-2030)
7.2.2 North America Antivenom Revenue by Country (2019-2030)
7.3 North America Antivenom Sales by Type (2019-2024)
7.4 North America Antivenom Sales by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Antivenom 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific Antivenom 麻豆原创 Facts & Figures by Region
8.2.1 Asia-Pacific Antivenom Sales by Region (2019-2030)
8.2.2 Asia-Pacific Antivenom Revenue by Region (2019-2030)
8.3 Asia-Pacific Antivenom Sales by Type (2019-2024)
8.4 Asia-Pacific Antivenom Sales by Application (2019-2024)
9 Europe
9.1 Europe Antivenom 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe Antivenom 麻豆原创 Facts & Figures by Country
9.2.1 Europe Antivenom Sales by Country (2019-2030)
9.2.2 Europe Antivenom Revenue by Country (2019-2030)
9.3 Europe Antivenom Sales by Type (2019-2024)
9.4 Europe Antivenom Sales by Application (2019-2024)
10 Latin America
10.1 Latin America Antivenom 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America Antivenom 麻豆原创 Facts & Figures by Country
10.2.1 Latin America Antivenom Sales by Country (2019-2030)
10.2.2 Latin America Antivenom Revenue by Country (2019-2030)
10.3 Latin America Antivenom Sales by Type (2019-2024)
10.4 Latin America Antivenom Sales by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Antivenom 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa Antivenom 麻豆原创 Facts & Figures by Country
11.2.1 Middle East and Africa Antivenom Sales by Country (2019-2030)
11.2.2 Middle East and Africa Antivenom Revenue by Country (2019-2030)
11.3 Middle East and Africa Antivenom Sales by Type (2019-2024)
11.4 Middle East and Africa Antivenom Sales by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Antivenom Supply Chain Analysis
12.2 Antivenom Key Raw Materials and Upstream Suppliers
12.3 Antivenom Clients Analysis
12.4 Antivenom Sales Channel and Sales Model Analysis
12.4.1 Antivenom Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Antivenom Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Antivenom Distributors
13 麻豆原创 Dynamics
13.1 Antivenom Industry Trends
13.2 Antivenom 麻豆原创 Drivers
13.3 Antivenom 麻豆原创 Challenges
13.4 Antivenom 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
听
听
*If Applicable.